title: [Treatment of infantile acute lymphoblastic leukemia with protocol ALL-BFM 83].
abstract: The outcome of 63 children with non-B acute lymphoblastic leukemia treated with ALL-BFM 83 protocol is analyzed. 95% achieved complete remission with the initial treatment. For the entire group the event free survival (EFS) was 66% (+/- 9%) at 48 months. These results were close to those obtained by the BFM group. Haematological toxicity was the main adverse effect, but there where no therapy related deaths. Persistence of more than 1,000 blast cells per microl in peripheral blood after 7th days of prednisone monotherapy, and spleen size greater than or equal to 5 cm under the costal margin, were identified as independent risk factors of high significance. The EFS in patients with poor clinical response to steroids (greater than or equal to 1,000 blast/microl at day 8) was 22% (+/- 18%), instead of 69% (+/- 12%) in those with adequate response.
authors.affiliation: Fundación Jiménez Díaz, Servicio de Pediatría, Madrid.
authors.forename: F J
authors.initials: FJ
authors.lastname: Aracil Santos
authors.forename: M
authors.initials: M
authors.lastname: Bernacer Borja
authors.forename: J
authors.initials: J
authors.lastname: López Pérez
authors.forename: C
authors.initials: C
authors.lastname: Melero Moreno
authors.forename: F
authors.initials: F
authors.lastname: Valverde Moreno
authors.forename: C
authors.initials: C
authors.lastname: Gil Gil
authors.forename: T
authors.initials: T
authors.lastname: Contra Gómez
authors.forename: N
authors.initials: N
authors.lastname: Martín Ramos
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D012074:Remission Induction
vernacular_title: Tratamiento de la leucemia aguda linfoblástica infantil con el protocolo ALL-BFM 83.